Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II
The real-world use of onabotulinumtoxinA and incobotulinumtoxinA for cervical dystonia and blepharospasm treatment was assessed in two separate retrospective studies using identical protocols (TRUDOSE and TRUDOSE II). The studies were conducted in Mexico, Norway, and United Kingdom and designed to e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/13/7/488 |
| _version_ | 1797526013341597696 |
|---|---|
| author | Ruth Kent Adrian Robertson Sandra Quiñones Aguilar Charalampos Tzoulis John Maltman |
| author_facet | Ruth Kent Adrian Robertson Sandra Quiñones Aguilar Charalampos Tzoulis John Maltman |
| author_sort | Ruth Kent |
| collection | DOAJ |
| description | The real-world use of onabotulinumtoxinA and incobotulinumtoxinA for cervical dystonia and blepharospasm treatment was assessed in two separate retrospective studies using identical protocols (TRUDOSE and TRUDOSE II). The studies were conducted in Mexico, Norway, and United Kingdom and designed to evaluate dose utilization of the two botulinum toxins in clinical practice. Eighty-three patients treated with both onabotulinumtoxinA and incobotulinumtoxinA for ≥2 years for each botulinum toxin were included, (52, cervical dystonia; 31, blepharospasm). All patients switched from onabotulinumtoxinA to incobotulinumtoxinA for administrative/financial reasons. A range of dose ratios (incobotulinumtoxinA to onabotulinumtoxinA) was reported; with the majority of dose ratios being >1. The mean dose ratio was >1 regardless of the study site or underlying clinical condition. The inter-injection interval was significantly longer for onabotulinumtoxinA versus incobotulinumtoxinA when assessed for all patients (15.5 vs. 14.3 weeks; <i>p</i> = 0.006), resulting in fewer onabotulinumtoxinA treatments over the study time period. Consistent with product labeling, no single fixed-dose ratio exists between incobotulinumtoxinA and onabotulinumtoxinA. The dosage of each should be individualized based on patient needs and used as per product labeling. These real-world utilization data may have pharmacoeconomic implications. |
| first_indexed | 2024-03-10T09:21:11Z |
| format | Article |
| id | doaj.art-e2484c7abe244cd7a2c7b6ec5a22c75a |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-10T09:21:11Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-e2484c7abe244cd7a2c7b6ec5a22c75a2023-11-22T05:11:02ZengMDPI AGToxins2072-66512021-07-0113748810.3390/toxins13070488Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE IIRuth Kent0Adrian Robertson1Sandra Quiñones Aguilar2Charalampos Tzoulis3John Maltman4Mid Yorkshire Hospitals NHS Trust, Wakefield WF20NJ, UKMid Yorkshire Hospitals NHS Trust, Wakefield WF20NJ, UKConsultorio de Medicina Especializada del Sector Privado, Mexico City 03100, MexicoHaukeland University Hospital, University of Bergen, 5021 Bergen, NorwayAllergan, Irvine, CA 92612, USAThe real-world use of onabotulinumtoxinA and incobotulinumtoxinA for cervical dystonia and blepharospasm treatment was assessed in two separate retrospective studies using identical protocols (TRUDOSE and TRUDOSE II). The studies were conducted in Mexico, Norway, and United Kingdom and designed to evaluate dose utilization of the two botulinum toxins in clinical practice. Eighty-three patients treated with both onabotulinumtoxinA and incobotulinumtoxinA for ≥2 years for each botulinum toxin were included, (52, cervical dystonia; 31, blepharospasm). All patients switched from onabotulinumtoxinA to incobotulinumtoxinA for administrative/financial reasons. A range of dose ratios (incobotulinumtoxinA to onabotulinumtoxinA) was reported; with the majority of dose ratios being >1. The mean dose ratio was >1 regardless of the study site or underlying clinical condition. The inter-injection interval was significantly longer for onabotulinumtoxinA versus incobotulinumtoxinA when assessed for all patients (15.5 vs. 14.3 weeks; <i>p</i> = 0.006), resulting in fewer onabotulinumtoxinA treatments over the study time period. Consistent with product labeling, no single fixed-dose ratio exists between incobotulinumtoxinA and onabotulinumtoxinA. The dosage of each should be individualized based on patient needs and used as per product labeling. These real-world utilization data may have pharmacoeconomic implications.https://www.mdpi.com/2072-6651/13/7/488botulinum toxinstype Areal-world usecervical dystoniablepharospasm |
| spellingShingle | Ruth Kent Adrian Robertson Sandra Quiñones Aguilar Charalampos Tzoulis John Maltman Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II Toxins botulinum toxins type A real-world use cervical dystonia blepharospasm |
| title | Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II |
| title_full | Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II |
| title_fullStr | Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II |
| title_full_unstemmed | Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II |
| title_short | Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II |
| title_sort | real world dosing of onabotulinumtoxina and incobotulinumtoxina for cervical dystonia and blepharospasm results from trudose and trudose ii |
| topic | botulinum toxins type A real-world use cervical dystonia blepharospasm |
| url | https://www.mdpi.com/2072-6651/13/7/488 |
| work_keys_str_mv | AT ruthkent realworlddosingofonabotulinumtoxinaandincobotulinumtoxinaforcervicaldystoniaandblepharospasmresultsfromtrudoseandtrudoseii AT adrianrobertson realworlddosingofonabotulinumtoxinaandincobotulinumtoxinaforcervicaldystoniaandblepharospasmresultsfromtrudoseandtrudoseii AT sandraquinonesaguilar realworlddosingofonabotulinumtoxinaandincobotulinumtoxinaforcervicaldystoniaandblepharospasmresultsfromtrudoseandtrudoseii AT charalampostzoulis realworlddosingofonabotulinumtoxinaandincobotulinumtoxinaforcervicaldystoniaandblepharospasmresultsfromtrudoseandtrudoseii AT johnmaltman realworlddosingofonabotulinumtoxinaandincobotulinumtoxinaforcervicaldystoniaandblepharospasmresultsfromtrudoseandtrudoseii |